What We Do
We translate scientific breakthroughs into investment opportunities that institutional capital understands.
Most pharmaceutical and medical device companies struggle at a critical inflection point. The science is proven. Patents are secured. Early funding is exhausted. They need capital for clinical trials, FDA approval, and commercial launch. But they speak research language while institutional investors speak business language.
We bridge that gap.
We work with companies developing treatments for cancer, autoimmune diseases, cardiovascular conditions, neurological disorders, and medical devices that improve patient outcomes. Stage doesn't matter. Technology and values do.
Who We Work With
We work with a limited number of clients at any given time. Every company passes comprehensive due diligence before we agree to represent them. Companies that don't meet our standards don't advance, regardless of how promising the technology appears.
We only work with founders who believe healthcare is a human right and are building technology that genuinely improves patient outcomes.
For institutional investors and family offices, this means pre-vetted deal flow in healthcare innovation. Companies that have been rigorously screened and properly positioned for capital deployment, saving you months of sorting through unqualified pitches.
We take equity in every engagement because we only succeed when the technology reaches patients.